Post by Apellis Pharmaceuticals

More than 1 million doses of our approved medicine have been administered to people living with geographic atrophy (GA), secondary to age-related macular degeneration — a milestone that reflects the impact we’re making for the GA community. Behind every dose is a patient taking an active role in managing their disease and an eye care provider committed to helping slow the progression of GA, a leading cause of irreversible vision loss. We’re proud to help transform care for people living with GA.